Special Evaluation of Recombinant Human Granulocyte Colony-stimulating Factor for the Adjuvant Treatment after Chemotherapy in Breast Cancer

OBJECTIVE To analysis the utilization of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in adjuvant treatment after chemotherapy in breast cancer, in order to improve the rationality of these drugs in patients with tumor undergoing chemotherapy. METHODS To select 150 cases from all the medical record in Xiamen Maternity and Child Health Care Hospital in 2016 of chemotherapy in breast cancer. Establishing evaluation criterion to analysis the indication, appropriate time, usage and dosage of rhG-CSF, et al. RESULTS rhG-CSF was used for adjuvant treatment after chemotherapy in breast cancer in Xiamen Maternity and Child Health Care Hospital. Unresonable prophylactic use was mainly in inappropriate time (accounting for 20.22%) while unreasonable therapeutic use was mainly in indication (accounting for 26.23%). CONCLUSION Monitoring and assessment of these drugs shall be enhanced while searching for the better evidence in order to promote rational drug use.